Chinese Antibody-drug Conjugates (ADCs) Licensed Overseas Exceeds $23 Billion This Year

by Grace Wang Dec 21, 2023

On December 20, 2023, Hansoh Pharma, a Chinese biopharma company, announced that it had reached an exclusive deal with GSK for HS-20093, an antibody-drug conjugate (ADC) targeting B7-H3.

Under the agreement, GSK will pay USD 185 million upfront, along with potential milestone payments of up to USD 1.525 billion, for the development and commercialization of HS-20093 worldwide excluding China’s mainland, Hong Kong, Macao, and Taiwan. 

This deal is one of 15 cross-border licensing deals inked this year between Chinese ADC-focused companies and multinational corporations this year.

Among these deals, the transaction between Biokin Pharmaceutical and BMS stands out with the highest total value of USD 8.4 billion. The overall value of the Chinese ADC licensing deals that took place this year has surpassed USD 23 billion. 

Table: Cross-border Deals with ADCs Licensed from Chinese Companies to Foreign Companies in 2023

ADC

Licensor

Licensee

Total value (USD million)

Announced

BL-B01D1

Biokin pharmaceutical

BMS

8,400

12/12/2023

BB-1701

BlissBio

Eisai

2,000

08/05/2023

HS-20093

Hansoh Pharma

GSK

1,701

20/12/2023

DB-1303; DB-1313

DualityBio

BioNTech

1,670

03/04/2023

HS-20089

Hansoh Pharma

GSK

1,570

20/10/2023

SHR-A1904

Jiangsu Hengrui Pharmaceuticals

Merck

EUR 1,400 million (circa USD 1,530 million)

30/10/2023

CMG901

KYM Biosciences

AstraZeneca

1,163

23/02/2023

HBM9033

Harbour Biomed

Pfizer

1,103

15/12/2023

GQ1010

GeneQuantum Healthcare

Pyramid Biosciences

1,020

22/04/2023

YL-202

MediLink Therapeutics

BioNTech

1,000

12/10/2023

A novel ADC for treating solid tumors

Evopoint Bio

AmMax Bio

871

09/01/2023

SYS-6002

CSPC Pharma

Corbus

692.5

23/02/2023

LM-305

LaNova Medicines

AstraZeneca

600

12/05/2023

DITAC platform

DualityBio

Adcendo

Not revealed

05/01/2023

DB-1305

DualityBio

BioNTech

Not revealed

07/08/2023

Related: Biopharma Licensing Deals Involving Chinese Companies in H1 2023

Subscribe to ChemLinked BaiPharm Newsletter.png

Grace Wang
ChemLinked Regulatory Analyst & Editor
+ FOLLOW
Copyright: unless otherwise stated all contents of this website are ©2024 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact cleditor@chemlinked.com
You May Also Like
Most Popular